You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

New Horizons in Managing Generalized Pustular Psoriasis

  • Authors: Richard B. Warren, MD, PhD; Melinda Gooderham, MD, MSc, FRCP; Diamant Thaçi, MD; Kristina Cranfield
  • CPD Released: 9/27/2022
  • Valid for credit through: 9/27/2023
Start Activity

  • Credits Available

    Non-US Physicians - maximum of 1.00 CPD

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This activity is intended for international audience of non-US dermatologists and primary care physicians.

The goal of this activity is that learners will be better able to highlight the impact of GPP on patients' lives, address the challenges in managing patients using off-label treatments, and highlight the rationale and latest clinical data with emerging therapies.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Impact of GPP on patients' lives
    • Clinical data for new agents targeting the interleukin-36 pathway
  • Have greater competence related to
    • Treatment selection for a patient with GPP


Disclosures

WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.

Disclosures for additional planners can be found here.


Chair

  • Richard B. Warren, MD, PhD

    Consultant Dermatologist
    Salford Royal NHS Foundation Trust
    Director of Dermatopharmacology Unit
    The University of Manchester
    Manchester, United Kingdom

    Disclosures

    Richard B. Warren, MD, PhD, has no relevant financial relationships.

Faculty

  • Melinda Gooderham, MD, MSc, FRCP

    Assistant Professor
    Queens University
    Medical Director
    SKiN Centre for Dermatology
    Peterborough, Ontario, Canada

    Disclosures

    Melinda Gooderham, MD, MSc, FRCP, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie Inc.; Akros Pharma Inc.; Amgen; Arena Pharmaceuticals; Arcutis Pharmaceuticals Inc.; Asana BioSciences; Aslan Pharmaceuticals; Bausch Health; Boehringer Ingelheim International GmbH; Celgene Corporation; Eli Lilly and Company; Galderma SA.; Janssen Inc.; Kyowa Kirin; Leo Pharma; Novartis Pharmaceuticals; Pfizer Inc.; Regeneron Pharmaceuticals Inc.; Sanofi Genzyme; Sun Pharmaceuticals; UCB
    Speaker or member of speakers bureau for: AbbVie Inc.; Amgen; Bausch Health; Boehringer Ingelheim International GmbH; Celgene Corporation; Eli Lilly and Company; Galderma SA.; Janssen Inc.; Merck and Co.; Novartis Pharmaceuticals; Pfizer Inc.; Roche Laboratories; Sanofi Genzyme; Sun Pharmaceuticals; UCB
    Contracted researcher for: AbbVie Inc.; Akros Pharma Inc.; Amgen; AnaptysBio; Arcutis Pharmaceuticals Inc.; Aslan Pharmaceuticals; Bausch Health; Boehringer Ingelheim International GmbH; Bristol Myers Squibb Company; Celgene Corporation; Coherus Biosciences; Dermira Inc.; Eli Lilly and Company; Galderma SA.; GlaxoSmithKline; Incyte; Janssen Inc.; Kyowa Kirin; Leo Pharma; MedImmune; Merck and Co.; Novartis Pharmaceuticals; Pfizer Inc.; Regeneron Pharmaceuticals Inc.; Roche Laboratories; Sanofi Genzyme; Sun Pharmaceuticals; Takeda Pharmaceuticals; UCB

  • Diamant Thaçi, MD

    Professor and Head
    Comprehensive Center for Inflammation Medicine
    University of Lübeck
    Lübeck, Germany

    Disclosures

    Diamant Thaçi, MD, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie Inc.; Almirall; Amgen; Asana BioSciences; BIOCAD; Biogen Idec; Boehringer Ingelheim; Bristol Myers Squibb; Celgene; DS Biopharma; GlaxoSmithKline; Janssen-Cilag; Kyowa Kirin; Leo Pharma; Eli Lilly; Novartis; Regeneron; Sandoz; Sanofi-Aventis; UCB
    Speaker or member of speakers bureau for: AbbVie; Almirall; Amgen; Asana BioSciences; BIOCAD; Biogen Idec; Boehringer Ingelheim; Bristol Myers Squibb; Celgene; DS Biopharma; GlaxoSmithKline; Janssen-Cilag; Kyowa Kirin; Leo Pharma; Eli Lilly; Novartis; Regeneron; Sandoz; Sanofi-Aventis; UCB
    Research funding from: AbbVie; Novartis

  • Kristina Cranfield

    Patient
    London, United Kingdom

    Disclosures

    Kristina Cranfield has no relevant financial relationships.

Editor

  • Marinella Calle, PhD, CMPP

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Marinella Calle, PhD, CMPP, has no relevant financial relationships.

Compliance Reviewer

  • Lisa Simani, APRN, MS, ACNP

    Associate Director, Accreditation and Compliance

    Disclosures

    Lisa Simani, APRN, MS, ACNP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 1.0 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

New Horizons in Managing Generalized Pustular Psoriasis

Authors: Richard B. Warren, MD, PhD; Melinda Gooderham, MD, MSc, FRCP; Diamant Thaçi, MD; Kristina CranfieldFaculty and Disclosures

CPD Released: 9/27/2022

Valid for credit through: 9/27/2023

processing....

Educational Impact Challenge

The goal of this activity is that learners will be better able to highlight the impact of GPP on patients' lives, address the challenges in managing patients using off-label treatments, and highlight the rationale and latest clinical data with emerging therapies.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.